Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Advaxis (ADXS) has provided an update.
Ayala Pharmaceuticals, Inc. finalized a major asset sale on March 25, 2024, leading to the departure of Chief Medical Officer Andres Guttierez. Following this transaction, Roy Golan, the Chief Financial Officer, also agreed to leave the company, with his departure set for June 25, 2024. This strategic move marks a significant reshuffling of Ayala’s executive team amidst its latest corporate developments.
For an in-depth examination of ADXS stock, go to TipRanks’ Stock Analysis page.